Objective: The Hancock II (HII) is a second-generation porcine bioprosthesis introduced into clinical use in 1982. This study aimed to evaluate very long-term outcomes for the HII valve in a large patient population. Methods: Between May 1983 and November 1993, 517 consecutive patients (pts) (309 male, mean age: 64 AE 9 years) underwent valve replacement (VR) surgery with HII, with 302 (58.4%) in the aortic VR (AVR) and 215 (41.6%) in the mitral VR (MVR) position, respectively. At implant, 106 pts (20.5%) were <60 years of age (G1), while 411 (79.5%) were !60 years of age (G2). The 25-year follow-up was complete for all pts at a median of 12 years (range: 0-25). Results: Long-term death occurred in 208 AVR and in 165 MVR pts. Survival at 15 and 20 years was 39.5% and 23.3% in AVR pts and 39.0% and 15.8% in MVR pts. At 25 years the survival of MVR pts was 13.7% (four pts at risk). Late freedom from re-operation was 85.5% and 79.3% at 15 and 20 years in the AVR pts and 73.3% and 52.8% in the MVR pts, respectively. In the AVR population, 20-year freedom from re-operation was 52.2% in G1 pts and 86.8% in G2 pts ( p < 0.0001), while in the MVR population it was 41.4% in G1 pts and 61.9% in G2 pts ( p = 0.201), respectively. Conclusions: These results confirm the excellent longterm performance of the HII bioprosthesis. #
Introduction
Many of the bioprosthetic heart valves that are currently commercially available entered clinical trails in the early 1980s. The majority of these are 'second-generation' devices that were developed to improve upon the limitations of the first-generation valves, namely haemodynamics and durability. Estimates of late durability for these valves, however, are confounded by patient survival, particularly when the majority of patients receiving bioprostheses have been older. Natural death in this population reduces the patient at risk over time presenting challenges for long-term follow-up. Reports of follow-up for these up to 20 years have been rare [1] [2] [3] [4] [5] .
The Hancock II (HII) bioprosthesis is representative of 'second-generation' bioprosthetic valves. It is the successor of the original Hancock Standard valve which was introduced in 1972. The HII (Medtronic, Inc., Minneapolis. Minnesota, USA) entered clinical use in 1982 featuring a lower implant profile, an anti-calcification agent (sodium dodecylsulfate or T-6), a minimised right coronary septal muscle-shelf and a two-stage fixation process (low followed by high pressure) [6] .
This retrospective multi-centre (Treviso Hospital and Padua University) study reports 25-year results for reoperation and survival with the HII valve.
Patients and methods

Patient population
Between May 1983 and November 1993, 517 patients consecutively received isolated aortic (302) or mitral (215) valve replacement (VR) when indicated for a bioprosthesis. Treviso implanted 365 of the valves and Padua 152. Concomitant tricuspid valve repairs are included in this population. The average age at implant was 64.4 AE 8.5 years (range: 20-90) with 79.5% of patients !60 years. Male gender represented 59.8% of the population. More specific demographic data may be found in Table 1 .
This population represents the patients enrolled in the first 10 years of a larger study published earlier by the authors [7] .
Surgical technique
Both institutions used the same operative technique. Implantation was done with inverted pledgeted sutures. Coronary artery-bypass grafting (CABG) was concomitantly performed when critical coronary artery lesions were present (70% disease). Other operative data are noted in Table 2 .
Follow-up
After securing approval at the respective hospital ethics committees, patients were followed by telephone or mail interview. Follow-up of this population was 100% complete. Median follow-up was 12.1 years (range: 0-24.7) for aortic VR (AVR) and 11.3 years (range: 0-25.2) for mitral VR (MVR) with 3539 and 2463 patient/years, respectively.
Statistical analysis
STATASE 9.0 (StataCorp, College Station, Texas, USA) was used for statistical analysis. Survival analysis uses the actuarial Kaplan-Meier method for patient survival and freedom from re-operation. Standard errors for these estimates are calculated with the formula of Peto and colleagues [8] . Survival was defined on a patient basis, so deaths were included as events if they occurred either with or without valve replacement. For the latest patients at risk, linearised event rates were used to represent complications per 100 patient years. The reverse Kaplan-Meier method was used to estimate the median follow-up time.
Results
Survival
Of the patients studied, 373 died -352 without reoperation and 21 after a re-operation. There were 144 survivors (94 AVR and 50 MVR) at follow-up. In the AVR population, overall survival was 66.2 AE 2.7%, 39.5 AE 2.9% and 23.3 AE 3.1% at 10, 15 and 20 years with 18 patients at risk in the 20th year ( Fig. 1A and Table 3 ). Survival favoured younger patients (<60 years) with one at risk at 24 years ( Fig. 1B and Table 3 ). Overall survival in the MVR population was 61.7 AE 3.3%, 39.0 AE 3.4% and 15.8 AE 3.0% at 10, 15 and 20 years ( Fig. 2A and Table 3 ), respectively. Again, survival favoured younger patients (<60 years) with four patients alive at 25 years ( Fig. 2B and Table 3 ). The linearised latemortality rates were 5.88% and 6.70% per patient-year, respectively, for AVR and MVR. The reverse Kaplan-Meier median follow-up was 18.0 years (95% confidence interval (CI): 17.6-18.5) for AVR and 20.0 (95% CI: 18.0-22.0) for MVR.
Re-operation
Of the AVR cohort, 30 (9.9%) patients required reoperation during the follow-up period. Freedom from reoperation was 94.6 AE 1.5%, 85.5 AE 2.7% and 79.3 AE 4.4% at 10, 15 and 20 years ( Fig. 3A and Table 3 ). The linearised rate Table 2 Operative data. 
Discussion
This article reports results up to 25 years experience with the HII bioprostheses. As such, it is the longest follow-up of a second-generation valve reported to date. Overall survival in a population with nearly 80% of the patients over 60 years of age is very satisfactory. Re-operation results in our present experience are particularly gratifying with overall actuarial freedom from events of 79.3% for AVR and 52.8% MVR, respectively, at 20 years. For the patient age group for which bioprostheses are most commonly indicated (!60 years) the results are particularly gratifying with 86.8% and 61.9% freedom from re-operation for AVR and MVR, respectively.
There have been a number of recent reports of '20-year experience' with bioprostheses in the literature. However, time of experience should not be confused with clear results of the experience. That is to say, some papers have few if any patients at risk at 20 years and/or years at which assessments are made are <20 years. For example, Myken and BechHansen's report on the Biocor valve (St. Jude Medical, St. Paul, MN, USA) covers experience up to 20 years but, clearly, has no follow-up of patients at 20 years as there are no patients at risk to this time point [1] . In the report by Jamieson and colleagues on the Carpentier-Edwards SAV (Edwards Lifesciences, Irvine, California, USA) there are patients at risk at 20 years, but the majority of assessments for outcomes are performed on follow-up to 18 years where numbers of patients at risk are reasonable [2] . This may provide more accurate assessment but cannot truly suggest expectation for the device's performance at 20 years. Our report, thus, differs in this regard as follow-up is truly at 20 years for the valve cohort. Result comparisons are thus limited by the ability to compare at different time points. Bioprostheses are typically indicated for use in older patients (!60 years of age) for whom natural death diminishes the number of patients surviving at follow-up points [9] . This is especially true when follow-up is up to two decades following implant. When one considers this simply -when the average patient age at implant is 64 years, the average age of survivors at 20 years will be 84 -the impact on late survival can be appreciated. This significantly impacts the number of patients at risk in late follow-up typically resulting in very few patients at risk, perhaps too few to allow for one to assume that the late results are truly representative. This plagues many late follow-up articles including another experience for HII by Borger and colleagues and recent results for the Biocor and Mitroflow valves [1, 2, 4] . Our outcome results compare well with other late reports. Table 4 compares patients at risk for the latest follow-up point for which freedom from event assessment is made. It should be noted that literature comparisons must be weighed with the understanding that they are confounded by differences in baseline cohort characteristics in addition to the late reporting differences noted above.
In our experience, the Kaplan-Meier late survival for AVR was 23.3% at 20 years and 16.2% for MVR at 19 years. This Table 4 Comparison of late'20-year' survival and re-operation. Table 4 . We acknowledge that conventional reporting for reoperation focusses on the most common cause, structural valve deterioration (SVD) [1] [2] [3] [4] [5] . However, the cause of reoperation is of little consequence to the patient, health-care system, etc., as it is the re-operation itself that is the most significant impact to these groups. Of greater importance is the rate and timing of re-operation. Of course, the cause of failure may impact the surgeon in terms of therapy, timing of surgery, etc., but we would argue that comparing SVD is problematic given different definitions for reporting. For example, explant for SVD may under-report events while SVD, according to Edmunds and colleagues, Guidelines for Reporting Morbidity and Mortality after Cardiac Valvular Operations, may over-report intrinsic device failure [11, 12] . The Edmunds guidelines specifically exclude re-operation for thromboembolism, prosthesis-patient mismatch, pannus, impingement, prosthetic valve endocarditis, etc., as SVD; however, these are not uncommon causes for re-operation. We thus opted for all-cause re-operation as a comparable follow-up outcome. Our HII results for re-operation, with a low number of re-operations over a long follow-up period, compare very favourably with other reports for overall age (Table 4) . Comparison by age group is not possible as this level of detail is typically reserved for the smaller re-operation subset of SVD.
In conclusion, the results we report demonstrate good late survival and excellent freedom from re-operation when compared to late experience with other bioprosthetic valves.
continuing experience the Hancock valve with the other biological valves, tissue valves, used in different ages. Of course in our study, patients below 60 represent one-fourth of the cases, while older patients are in the majority. We have seen that you can safely implant the Hancock valve at different age decades, even below 60, because we saw a very clear relationship between durability of the valve and age of the patient at implant. So from age 60 you can always safely implant a Hancock because of the durability, but even for a patient at 50 years of age, you have a high chance, 85%, of having a still-functioning valve at 15 years. So I think this is a very important message.
The previous presentation was about stentless versus stented valves and Dr Mohr knows perfectly that we did follow quite the same experience. In effect, the quality of life with the stentless valve could temporarily give a little better result. But you have to focus on the kind of pathology. Our experience just presented considers the decade between '83 and '93, during which we had patients referred by cardiologists that were affected in prevalence by a pure valvular pathology; it means that very small associated pathologies were present. In a few words, we have been able to consider almost only valvular disease. In conclusion, basing on the results in terms of durability, the Hancock II represents the gold standard.
